

\$5.5 million in Firm Sub-underwriting Commitments

Secured for RHYO Options

Highlights

- ✓ **Binding sub-underwriting commitments of \$5.5 million in funding (before costs) secured from underwriting in respect of Listed Options, ASX: RHYO.**

Melbourne, Australia, 27 February 2026: Rhythm Biosciences Ltd (“RHY”, the “Company” or the “Group”) (ASX: RHY), a transformative, predictive cancer diagnostics technology company advises that the CPS Capital Group Pty Ltd (“CPS”, the “Underwriter”) has secured binding sub-underwriting commitments totalling \$5.5 million (before costs) under the previously announced Underwriting Agreement dated 25 February 2026 relating to the partial underwriting of Listed Options (ASX: RHYO) exercisable at \$0.20 each and expiring at 5:00pm (AEST) on 31 March 2026 (“Listed Options”).

These commitments represent a significant proportion of the underwritten amount and have been received from a range of sophisticated investors.

These commitments are subject to customary conditions and termination events under the Underwriting Agreement and as set out in Annexure A of the Company’s announcement on 25 February 2026.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

Directors

Gavin Fox-Smith
Sue MacLeman
David Atkins

Non-Executive Chairman
Non-Executive Director
CO & Managing Director

www.rhythmbio.com

T +61 3 8256 2880
E info@rhythmbio.com

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.